Bronchopulmonary Pathology Prevalence Among Premature infants and Estimation of Prophylactic Efficacy and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Premature infants with Bronchopulmonary Dysplasia

Background. The most frequent chronic lung pathology among infants and especially in premature children with extremely low and very low body weight is bronchopulmonary dysplasia (BPD).

The aim of the study is to study the prevalence of bronchopulmonary pathology among premature children and justify the need to vaccinate against pneumococcal disease premature children suffering from BPD.

Methods. The official statistics (Form №32) and data from annual reports of the catamnesis department of “the Honourary order” Perm Regional Clinical Hospital were used in order to measure the number of premature children born alive in Perm region in 2015-2017 yy. The estimation of prophylactic efficacy and reactogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) at immunization of premature children with BPD.

Results. The study group included vaccinated premature children with BPD (n=29), the experimental group included non-vaccinated premature children with BPD (n=29) and 30 vaccinated term children. Administration of PCV13 in premature children suffering from BPD has revealed its high prophylactic efficacy (no cases of community-acquired pneumonia among vaccinated children during the prospective study for 3 years), high tolerability (no cases of broncho-obstructive syndrome or negative effects on respiratory system such as apnoea or desaturation among vaccinated children). Low reactogenicity (17.2 ± 0.57%) and similar vaccine tolerance with term children (16.5 ± 0.55%) has been revealed as well. The combination of PCV13 with other vaccines from immunisation schedule did not increase the number of vaccine-induced diseases in comparison with administration of PCV13 alone.

Conclusion. The scientific necessity of vaccination of premature children with BPD against pneumococcal disease has been proved. The high prophylactic efficacy and low reactogenicity of PCV13 in this children group at tertiary neonatological care (catamnesis department of perinatal center) has been established within the national immunisation schedule.

1. Partnership for Maternal, Newborn & Child Health [Internet]. Born too soon: the global action report on preterm birth. WHO: New York; 2019. [cited 2012 May 2] Available from: https://www.who.int/pmnch/media/news/2012/preterm_birth_report/en/index3.html.

2. Kharit SM, Fridman IV, Pavlyukova AN, et al. Clinical efficacy of Pneumococcal conjugate 13-valent vaccine in young children. Pediatric pharmacology. 2016;13(5):443–447. (In Russ). doi: 10.15690/pf.v13i5.1639.

3. Feldblium IV, Bikmieva AV, Zakharova YA, et al. Analysis of the compliance of the vaccination schedule against Pneumococcal infection in young children. Epidemiology and vaccinal prevention. 2018;17(5):111–116. (In Russ). doi: 10.31631/2073-3046-2018-17-5-111-116.

4. Tatochenko VK. Vaccination of premature low-birth-weight children. Pediatric pharmacology. 2013;10(4):30–36. (In Russ). doi: 10.15690/pf.v10i4.752.

5. Martinón-Torres F, Czajka H, Center KJ, et al. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. Pediatrics. 2015;135(4):876–886. doi: 10.1542/peds.2014-2941.

6. Il’ina SV, Lyisanov YuI. Vaccination of premature infants and children with congenital heart disease in Irkutsk using conjugated pneumococcal vaccines. Pediatric pharmacology. 2013;10(3):12–16. (In Russ). doi: 10.15690/pf.v10i3.692.

7. Panchenko AS, Gaimolenko IN, Tichonenko OA, Ignatieva AV. Bronchopulmonary dysplasia: treatment, diagnostics, results. Zabaykal’skiy meditsinskiy vestnik. 2013;(1):175–183. (In Russ). doi: 10.17750/KMJ2016-346.8.

8. Kair LR, Jodee А, Leonard DT. Bronchopulmonary dysplasia. Pediatrics in Review. 2012;33(6):255–265. doi: 10.1542/pir.33-6-255.

9. Kholichev DA, Senkevich ОA, Filonov VA, et al. Bronchopulmonary dysplasia in children. Dal’nevostochnyy meditsinskiy zhurnal. 2014;(1):122–126. (In Russ).

10. Zubova ES, Semerikov VV, Sofronova LV, Kostinov MP. Assessment of safety, immunogenicity and preventive efficacy of Prevenar-13 in children with bronchopulmonary dysplasia. Epidemiology and vaccinal prevention. 2018;17(2): 65–69. (In Russ). doi: 10.24411/2073-3046-2018-10009.

11. Alvira CM. Aberrant pulmonary vascular growth and remodeling in bronchopulmonary dysplasia. Front Med (Lausanne). 2016;3:21. doi: 10.3389/fmed.2016.00021.

12. D’Angio CT, Maniscalco WM. Bronchopulmonary dysplasia in preterm infants. Pathophysiology and management strategies. Paediatr Drugs. 2004;6(5):303–330. doi: 10.2165/00148581-200406050-00004.

13. Davidova IV, NamazovaBaranova LS, Kazakova KA, Fedoseenko MV, et al. Immunization of bronchopulmonary dysplasia patients against respiratory pathogens. Russian Pediatric Journal. 2017;20(4):245–249. (In Russ). doi: 10.15690/pf.v15i1.1842.

14. Kazakova KA, Namazova-Baranova LS, Davidova IV. Primary serological status and immunological efficacy of vaccination against Streptococcus pneumoniae and Haemophilus type B in children with bronchopulmonary dysplasia: a cohort study. Pediatric pharmacology. 2018;15(1):43– 49. (In Russ). doi: 10.15690/pf.v15i1.1842.